Electromyographic Study for the Help and Guidance of BoNTA Administration in the Treatment of Chronic Pelvic Floor Pain

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-29

Study Completion Date

2020-04-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic pelvic pain (CPP) is a common presenting complaint affecting approximately 15-40 % of women aged 18-50 in western countries and 5-43% of women in most developing countries. It is debilitating and has a large socio- economic impact, with a 45%reduction in work productivity, and a 15% increase in absence from work in women with the condition. Botulinum neurotoxin type A (BoNTA) has been suggested to improve pain in muscle spasm, its role in CPP secondary to pelvic floor spasm has gained increasing interest. However, clinicians do not have a diagnosis tool to evaluate the CPP and the BoNTA treatment results.

Design and develop an efficient and simple tool for the diagnosis and detection of pelvic floor muscle (PFM) dysfunction based on superficial electromyography (EMG) and perform 25 EMG registrations sessions in healthy patients and 25 EMG sessions in patients diagnoses with PFM that will be treated with BoNTA to and study the EMG signal before and after BoNTA administration.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Injection With OnabotulinumtoxinA (Botox) for the Treatment of Chronic Pelvic Pain

NCT02173405

Myofascial Pain Syndromes Myofascial Trigger Point Pain Trigger Point Pain, Myofascial

COMPLETED PHASE1

EMG Guided Botulinum Toxin Type A Injections for Refractory High Tone Pelvic Floor Dysfunction

NCT01323829

High Tone Pelvic Floor Dysfunction

COMPLETED NA

Botulinum Toxin for Pelvic Pain in Women With Endometriosis

NCT01553201

Endometriosis Chronic Pelvic Pain Pelvic Muscle Spasm +1 more

COMPLETED PHASE1/PHASE2

Botulinum Toxin Type A Versus Saline Trigger Point Injections for Myofascial Pelvic Pain

NCT01905137

Myofascial Pelvic Pain

UNKNOWN NA

BTA vs Baclofen for Pelvic Myofascial Pain Syndrome

NCT05617118

Chronic Pain Chronic Pelvic Pain Syndrome Myofascial Pain Syndrome +2 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Electromyography EMG: Myopathy EMG Syndrome Pelvic Pain Pelvic Floor Disorders Pelvic Pain Syndrome ElectroPhys: Myopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BoNTA Injection

Patients diagnosed with chronic pelvic floor pain, without contraindications for the administration of BoNTA.

Name of each active substance (INN or proposed INN if available):

Botulinum toxin type A Clostridium botulinum type A (BoNTA) Pharmaceutical form (use standard terms): Powder and solution for solution for injection Route of administration (relevant to the maximum dose): Intramuscular use Specify total dose : 80 U

Group Type EXPERIMENTAL

Clostridium botulinum type A (BoNTA)

Intervention Type DRUG

Powder and solution for solution for injection Specify total dose: 80 U

Route of administration:

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clostridium botulinum type A (BoNTA)

Powder and solution for solution for injection Specify total dose: 80 U

Route of administration:

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BoNTA Clostridium botulinum type A

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

I. Chronic pelvic floor pain (CPD) is defined as pain lasting longer than six months, with absence of proven organic cause and finding of component myofascial present that has been refractory to conventional medical treatment (NSAIDs) II. Sign Informed Consent for the administration of BoNTA III. Authorize to participate in the study IV. Patients who agree not to become pregnant during the duration of the study, using effective contraceptive methods

Exclusion Criteria

I. Minor II. Pelvic active infection III. General or pelvic malignant disease IV. Psychiatric disease V. Contraindication for the administration of BoNTA VI. Patients who participate in another clinical trial and have been administered a investigational medication within 30 days prior to the planned start of the treatment.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No